Athanasia K. Papazafiropoulou*, Andreas Melidonis and Stavros Antonopoulos Pages 1035 - 1042 ( 8 )
During the last decade, the results of large-scale, randomized, clinical trials on newer antidiabetic agents, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter type 2 (SGLT2) inhibitor, have been published showing promising findings on cardiovascular and renal outcomes. Besides improving glycemic control, GLP-1 receptor agonists have been shown to modify cardiovascular risk factors, such as insulin resistance, body weight, blood pressure (BP), and lipid profile. Additionally, SGLT2 inhibitors except for glycemic control have been shown to induce weight loss and decrease BP. However, there are limited data regarding their effect on patients without diabetes. Therefore, the aim of the present review is to summarize the existing literature data regarding the effects of newer antidiabetic therapies on patients without diabetes.
Non-diabetic, SGLT2 inhibitors, GLP-1 receptor agonists, empagliflozin, dapagliflozin, canagliflozin, liraglutide, dulaglutide, exenatide, semaglutide.
1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Diabetes and Cardiometabolic Center, Μetropolitan Hospital, Piraeus, Piraeus, 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus